Description
British Dispensary FLUX Ipamorelin + GHRP-2 + CJC-1295 is a premium multi-peptide research formulation combining Ipamorelin, GHRP-2 (Growth Hormone Releasing Peptide-2), and CJC-1295 into a single advanced investigational blend. Developed exclusively for laboratory research, this synergistic peptide combination is extensively investigated for its role in growth hormone physiology, pituitary signaling, endocrine regulation, peptide pharmacology, and molecular endocrinology through complementary biological mechanisms.
By combining two Growth Hormone Secretagogues (GHSs) with a Growth Hormone-Releasing Hormone (GHRH) analog, FLUX Ipamorelin + GHRP-2 + CJC-1295 provides researchers with a comprehensive platform for studying Growth Hormone Secretagogue Receptor (GHS-R1a) signaling, Growth Hormone-Releasing Hormone Receptor (GHRH-R) activation, IGF-1 regulation, intracellular communication, and endocrine feedback mechanisms.
Each package contains 5 sterile vials, with Ipamorelin 2 mg, GHRP-2 2 mg, and CJC-1295 2 mg per vial, providing a total peptide concentration of 6 mg per vial. Manufactured by British Dispensary under stringent pharmaceutical-quality standards, every batch undergoes comprehensive quality testing to ensure exceptional purity, peptide integrity, and dependable laboratory performance.
Key Features
- Premium multi-peptide research formulation
- 5 sterile vials per package
- Ipamorelin – 2 mg per vial
- GHRP-2 (Growth Hormone Releasing Peptide-2) – 2 mg per vial
- CJC-1295 – 2 mg per vial
- Total peptide concentration: 6 mg per vial
- Combines two Growth Hormone Secretagogues with a GHRH analog
- High-purity laboratory-grade peptide formulation
- Suitable for investigations involving growth hormone physiology, pituitary biology, GHS-R1a signaling, GHRH receptor activation, IGF-1 regulation, peptide pharmacology, intracellular signaling, and molecular endocrinology
- Manufactured under rigorous pharmaceutical-quality standards
- Intended exclusively for laboratory and scientific research applications
How It Works
FLUX Ipamorelin + GHRP-2 + CJC-1295 combines three investigational peptides with complementary biological mechanisms, allowing researchers to investigate multiple endocrine pathways within a single laboratory model.
- Ipamorelin – 2 mg is a selective Growth Hormone Secretagogue (GHS) that activates the Growth Hormone Secretagogue Receptor (GHS-R1a). Researchers investigate its role in growth hormone physiology, peptide signaling, receptor pharmacology, and endocrine regulation.
- GHRP-2 – 2 mg is a synthetic Growth Hormone Secretagogue that also targets the GHS-R1a receptor, making it valuable for studies involving growth hormone secretion, pituitary physiology, ghrelin receptor biology, and intracellular signaling.
- CJC-1295 – 2 mg is a synthetic Growth Hormone-Releasing Hormone (GHRH) analog that selectively activates the Growth Hormone-Releasing Hormone Receptor (GHRH-R), enabling investigations into growth hormone release, IGF-1 regulation, receptor pharmacology, and endocrine communication.
Together, these complementary peptides provide researchers with a comprehensive platform for investigating growth hormone regulation, pituitary signaling, peptide-receptor interactions, endocrine physiology, IGF-1 biology, cellular communication, peptide pharmacology, and molecular endocrinology.
This formulation is intended exclusively for laboratory and scientific research and is not intended for human consumption.
Contents
Active Ingredients (Per Vial):
- Ipamorelin – 2 mg
- GHRP-2 – 2 mg
- CJC-1295 – 2 mg
Total Peptide Concentration: 6 mg per Vial
Packaging:
- 5 Sterile Vials
Reviews
There are no reviews yet.